On December 22, 2025, the FDA approved Novo Nordisk's once-daily oral semaglutide (branded as the Wegovy pill), marking the first oral GLP-1 receptor agonist specifically for chronic weight management in adults with obesity or overweight (with at least one weight-related comorbidity).
